InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
wiltonio Free
06/09/17 4:10 PM
profile icon
stocktrademan Free
05/17/15 12:48 PM
profile icon
stocktrademan Free
11/24/14 1:46 PM
profile icon
RWIII Free
01/14/14 10:56 AM
profile icon
zelskid Free
11/12/13 9:32 AM
profile icon
fredugsi Free
11/06/13 12:17 PM
profile icon
zelskid Free
11/06/13 10:56 AM
profile icon
fredugsi Free
10/31/13 11:35 AM
profile icon
zelskid Free
10/31/13 9:51 AM
profile icon
zelskid Free
10/30/13 10:40 AM
profile icon
fredugsi Free
10/22/13 5:06 PM
profile icon
zelskid Free
10/16/13 5:00 PM
profile icon
zelskid Free
10/15/13 4:06 PM
profile icon
zelskid Free
10/15/13 10:53 AM
profile icon
zelskid Free
10/01/13 7:17 PM
profile icon
zelskid Free
09/26/13 7:17 PM
profile icon
zelskid Free
09/26/13 4:02 PM
profile icon
zelskid Free
09/26/13 2:41 PM
profile icon
zelskid Free
09/26/13 10:05 AM
profile icon
zelskid Free
09/23/13 4:12 PM
profile icon
zelskid Free
09/23/13 10:52 AM
profile icon
zelskid Free
09/20/13 2:56 PM
profile icon
zelskid Free
09/12/13 10:05 AM

NanoString Technologies Inc (NSTGQ) RSS Feed

Followers
4
Posters
31
Posts (Today)
0
Posts (Total)
76
Created
09/12/13
Type
Free
Moderators
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Prosigna(TM) Breast Cancer Prognostic Gene Signature Assay. Based on the PAM50 gene signature, Prosigna is the company's first FDA-cleared in vitro diagnostic assay and uses the gene expression profile of cells found in breast cancer tissue to assess a patient's risk of distant recurrence of disease. The Prosigna Assay is performed using the nCounter(R) Dx Analysis System, which can be placed in qualified laboratories throughout the United States, empowering oncologists and pathologists to quickly and easily meet the testing needs of their breast cancer patients. "Receipt of FDA 510(k) clearance for Prosigna marks a key milestone for NanoString and is an important step forward in the treatment of breast cancer. This achievement is a testament to the ongoing dedication and professionalism of our team, and the commitment of our collaborators," said Brad Gray, President and Chief Executive Officer of NanoString Technologies. "Prosigna illustrates our approach of using nCounter technology to translate genomic discoveries into powerful in vitro diagnostic products, and it represents a significant growth opportunity beyond our robust life sciences research business." The Prosigna Assay is intended for use as a prognostic indicator for distant recurrence-free survival at 10 years, and is indicated for postmenopausal women with Stage I/II lymph node-negative or Stage II lymph node-positive (one to three positive nodes) hormone receptor-positive breast cancer who have undergone surgery in conjunction with locoregional treatment consistent with standard of care. For each patient, the Prosigna Assay reports the Prosigna Score (referred to as Risk of Recurrence Score, or ROR Score, in the scientific literature, including the TransATAC study recently published in the Journal of Clinical Oncology(1)) and a risk category based on both the Prosigna Score and nodal status. Node-negative patients are classified as low, intermediate or high risk, while node-positive patients are classified as low or high risk.
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post